Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deal Details 11
Asset Purchase 11
Cell Therapeutics Acquires Pacritinib From S*BIO 11
Venture Financing 13
CTI BioPharma Announces Venture Debt Financing 13
Licensing Agreements 14
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
Equity Offering 17
CTI BioPharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 18
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 20
CTI BioPharma Raises USD50 Million in Public Offering of Shares 22
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 24
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 26
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 28
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 29
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 31
Cell Therapeutics Completes Private Placement Of Series 14 Preferred Stock For US$20 Million 33
Cell Therapeutics Completes Private Placement Of Series 13 Preferred Stock For US$30 Million 34
Cell Therapeutics Completes Private Placement Of Series 12 Preferred Stock For US$16 Million 36
Cell Therapeutics Completes Private Placement Of US$25 Million 38
Cell Therapeutics Completes Registered Offering Of US$25 Million 40
CTI BioPharma Corp – Key Competitors 42
CTI BioPharma Corp – Key Employees 43
CTI BioPharma Corp – Locations And Subsidiaries 44
Head Office 44
Other Locations & Subsidiaries 44
Recent Developments 45
Financial Announcements 45
Nov 06, 2017: CTI BioPharma Reports Third Quarter 2017 Financial Results 45
Aug 03, 2017: CTI BioPharma Reports Second Quarter 2017 Financial Results 47
May 03, 2017: CTI BioPharma Reports First Quarter 2017 Financial Results 48
Mar 02, 2017: CTI BioPharma Reports Fourth Quarter and Full Year 2016 Financial Results 49
Nov 08, 2016: CTI BioPharma Reports Third Quarter 2016 Financial Results 51
Aug 04, 2016: CTI BioPharma Reports Second Quarter 2016 Financial Results 52
May 10, 2016: CTI BioPharma Reports First Quarter 2016 Financial Results 53
Feb 16, 2016: CTI BioPharma Reports Fourth Quarter And Full Year 2015 Financial Results 54
Corporate Communications 56
Sep 26, 2017: CTI BioPharma Appoints Laurent Fischer as New Chairman of the Board and Announces Management Promotions 56
Jul 24, 2017: CTI BioPharma Appoints Biotechnology Industry Veteran Laurent Fischer, M.D., to Board of Directors 57
Jun 05, 2017: CTI BioPharma Appoints David R. Parkinson, M.D., Leader in Oncology Clinical Development, to Board of Directors and Announces Board Member Resignations 58
Feb 27, 2017: CTI BioPharma Announces Appointment of Hematology/Oncology Clinical Expert Adam Craig, M.D., Ph.D., as President and CEO 59
Oct 03, 2016: CTI BioPharma Announces Retirement Of President And CEO 60
Jan 13, 2016: CTI BioPharma Appoints Matthew Perry To Board Of Directors 61
Product News 62
Dec 01, 2016: CTI BioPharma Presents Nonclinical Pharmacology Study Demonstrating Pacritinib Has Distinct Profile Amongst JAK Inhibitors At EORTC-NCI-AACR Molecular Targets And Cancer Therapeutics Symposium 62
05/19/2016: CTI BioPharma Announces Presentations At The American Society Of Clinical Oncology Annual Meeting 63
04/13/2016: CTI BioPharma Announces Presentation on pacritinib at the American Association of Cancer Research Annual Meeting 64
01/09/2017: CTI BioPharma Announces Progress Of Pacritinib And Strategic Objectives For 2017 66
Product Approvals 68
Mar 24, 2017: Withdrawal of the marketing authorisation application for Enpaxiq (pacritinib) 68
Feb 09, 2016: CTI BioPharma Provides Update On Clinical Hold Of Investigational Agent Pacritinib And New Drug Application In U.S. 69
Feb 08, 2016: CTI BioPharma Provides Update On Investigational Agent Pacritinib 70
Jan 05, 2016: CTI BioPharma And Baxalta Complete Submission Of New Drug Application For Pacritinib For Unmet Medical Need In Myelofibrosis 71
Clinical Trials 72
Jan 05, 2017: CTI BioPharma Announces Removal Of Full Clinical Hold On Pacritinib 72
Dec 06, 2016: PERSIST-2 Phase 3 Study Of Pacritinib Versus Best Available Therapy Shows Encouraging Clinical Activity In High-Risk Patients With Advanced Myelofibrosis In Late-Breaking Session At ASH Annual Meeting 74
Nov 21, 2016: CTI BioPharma Announces data on Pacritinib at ASH Annual Meeting 76
Aug 29, 2016: CTI BioPharma Announces Top-Line Results From PERSIST-2 Phase 3 Trial Of Pacritinib For High-Risk Patients With Advanced Myelofibrosis 78
Jun 07, 2016: Long-Term Follow Up Data For Pacritinib Presented At 2016 ASCO Annual Meeting 80
Apr 20, 2016: Preclinical Data Presented At AACR Indicate Pacritinib Potential To Eradicate Therapy-Resistant Leukemia Stem Cells Residing In Bone Marrow Microenvironment 83
Other Significant Developments 85
Jan 11, 2016: CTI BioPharma Announces Positive Progress Of Lead Clinical Programs And General Outlook For Transformational 2016 85
Appendix 87
Methodology 87
About GlobalData 87
Contact Us 87
Disclaimer 87
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2016 2
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 6
CTI BioPharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 7
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 8
CTI BioPharma Corp, Deals By Therapy Area, 2011 to YTD 2017 9
CTI BioPharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 10
Cell Therapeutics Acquires Pacritinib From S*BIO 11
CTI BioPharma Announces Venture Debt Financing 13
CTI BioPharma Enters into Licensing Agreement with Vernalis for tosedostat 14
Servier Expands Licensing Agreement with CTI BioPharma for Pixuvri 15
CTI BioPharma Plans to Raise up to USD200 Million in Public Offering of Securities 17
CTI BioPharma Raises USD45 Million in Public Offering of Series N-3 Preferred Stock 18
CTI BioPharma Raises USD55 Million in Public Offering of Series N-2 Preferred Stock 20
CTI BioPharma Raises USD50 Million in Public Offering of Shares 22
CTI BioPharma Raises USD15.7 Million in Private Placement of Shares 24
CTI BioPharma Raises USD35 Million in Public Offering of Preferred Shares 26
Cell Therapeutics Completes Private Placement Of Preferred Stock For US$15 Million 28
Cell Therapeutics Completes Public Offering Of Preferred Stock For US$60 Million 29
Cell Therapeutics Completes Second Tranche Of Private Placement Of Series 15-2 Convertible Preferred Stock For US$15 Million 31
Cell Therapeutics Completes Private Placement Of Series 14 Preferred Stock For US$20 Million 33
Cell Therapeutics Completes Private Placement Of Series 13 Preferred Stock For US$30 Million 34
Cell Therapeutics Completes Private Placement Of Series 12 Preferred Stock For US$16 Million 36
Cell Therapeutics Completes Private Placement Of US$25 Million 38
Cell Therapeutics Completes Registered Offering Of US$25 Million 40
CTI BioPharma Corp, Key Competitors 42
CTI BioPharma Corp, Key Employees 43
CTI BioPharma Corp, Subsidiaries 44